European Society for Medical Oncology

New data on combination treatments for melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according ...

Sep 29, 2014
popularity 0 comments 0

The true costs of cancer in Europe revealed

New studies that reveal for the first time the real economic and human costs of caring for cancer patients in Europe will be presented during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

Sep 28, 2012
popularity 0 comments 0